Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

nsidered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.", "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations." Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.ALEXZA PHARMACEUTICALS, INC.(a development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)

(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009Revenue

$
744$
-$
744$
9,514Operating expenses:Research and development

6,6549,18322,50832,153General and administrative

2,6103,82411,47411,893Restructuring charges

---2,153Acquired in-process research and development

----Total operating expenses

9,26413,00733,98246,199Loss
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Alvarado Hospital unveiled its new facility ... & Joint Institute. The institute is entirely devoted ... surgery and joint replacement. The Spine & Joint ... experience-focused approach. For example, patients are encouraged to ... than patient gowns. "From the ...
(Date:7/29/2015)... LAKE FOREST, Calif. , July 29, ... ) ("Cryoport" or the "Company"), the leading ... the life sciences industry, serving markets including ... organizations, vaccine manufacturers, animal health, and reproductive ... completed the sale of common stock and warrants ...
(Date:7/29/2015)...  Ortho-Clinical Diagnostics, Inc. (OCD) today announced the presentation ... address a range of important tests for clinical labs ... The scientific posters will be delivered during the 2015 ... held July 26 - 30 in Atlanta, ... is emerging stronger than ever since becoming a stand-alone ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... DIEGO, Feb. 11, 2011 Conatus Pharmaceuticals Inc. today ... Preferred Stock private placement financing.  This financing was led ... and included participation by existing investors; Aberdare Ventures, Advent ... Roche Venture Fund.  Conatus will use the proceeds to ...
... LOS ANGELES, Feb. 11, 2011 Nationally-acclaimed researcher and ... speech at the 11th National Conference on Cancer Nursing ... potentially deadly infections they were supposed to prevent. ... needleless IV connector devices with silver coated or silver ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to Chicago ... find a complete removable denture acceptable. The demand for dental implants is rising ... less expensive, immediate loading techniques will have the ability to offer the patient ...
(Date:7/30/2015)... ... 2015 , ... When trying to gain weight, many people place a lot of focus on the different types ... to be consumed. However, another key component to successful weight gain is knowing when ... this, CB-1 Weight Gainer gives three tips on when to eat to gain weight. ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, ... the newest installment in their popular DISC for the Real World series, will air ... webinar is intended for people interested in training others to use DISC behavioral analysis ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2
... WASHINGTON, April 8, 2008 The following is a,statement ... Governor Ted Strickland and Ohio legislators have abandoned ... their underhanded actions today to,raid funds from the Ohio ... to come more Ohio children will become addicted to,tobacco, ...
... Important to Protect Animal, Human Health, WASHINGTON, ... today launched its newly designed "Keeping Animals Healthy",website ... important,role of public policy in providing animal medicines ... are becoming more aware of the relationship between ...
... Filed in ... ... KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical,company that ... pharmaceutical,products, announced today that it has reached a comprehensive settlement,agreement ...
... Clinical Trial Results on Preoperative Chemotherapy in Early Breast ... no better than six cycles in women with early ... according to data from a randomized controlled trial. Additionally, ... cycles of one drug combination did not benefit from ...
... of the main obstacles towards progress in the developing ... that have not been seriously addressed by the public ... new book, Forgotten People, Forgotten Diseases, published by ASM ... the world have too long been ignored. Parasitic ...
... Ultravist(R) are part of Amerinet,s Portfolio of ... Contracted ... HealthCare,Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that,the ... to make,Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R),(iopromide) injection available to ...
Cached Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Other highlights in the April 8 JNCI 2Health News:Other highlights in the April 8 JNCI 3Health News:Other highlights in the April 8 JNCI 4Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 3Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 4
Arm Compression Garment...
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Bra...
Medicine Products: